Mirataz 2 % Ointment is a Health Canada–registered veterinary drug (DIN 02504626) held by Dechra Ltd, containing Mirtazapine. Health Canada lists its status as Marketed (status date 22 Jun 2021). Nexara Health has matched 759 registrations of Mirtazapine across 34 other regulated markets.

Health Canada registration

Mirtazapine registered in other markets

759 registrations of the same molecule in 34 national registries outside Canada (first 120 shown, exact strength and form first). Each row is taken from the regulator's own published list; status is shown as the registry reports it.

See every manufacturer of Mirtazapine worldwide →

Regulator price references for Mirtazapine

Published list or reimbursement prices for Mirtazapine presentations, in local currency, as at the date each registry last published. These are public reference prices, not Nexara Health quotes; strength and pack differ by row.

Sourcing through Nexara Health

Nexara Health is a Health Canada–licensed wholesaler (DEL #3-002896) in Winnipeg. Because this DIN is marketed in Canada, supply normally comes through the Canadian channel; where the Canadian presentation is short or discontinued, the registrations above show which regulated markets hold an equivalent that can be imported under the Special Access Programme or for clinical comparator use. Request a quote or read how named-patient and foreign-pack supply works in Canada.

Frequently asked questions

Is Mirataz (DIN 02504626) marketed in Canada?

Yes. Health Canada lists DIN 02504626 as Marketed as of 22 Jun 2021.

Who holds the Canadian licence for this product?

Dechra Ltd is the company of record in the Health Canada Drug Product Database.

Is Mirtazapine registered outside Canada?

Yes — Nexara Health has matched 759 registrations in 34 other markets (see the table above).

Where does this data come from?

Health Canada Drug Product Database (DPD), DIN 02504626, status date 2021-06-22; national medicine registries: BDA, CNOPS liste des medicaments, CNS liste positive, DH Drug Office, eEKO (Erstattungskodex), EMA centrally authorised, EU national register, Fimea Perusrekisteri, HPRA, HZZO, Laegemiddelstyrelsen, Lyfjastofnun lyfjaverdskra, Medicines Authority, MoH deltio timwn, NEAK PUPHA, NHRA, NPRA, PBS, SUKL DLP; price sources: EDE, eEKO (Erstattungskodex), Lyfjastofnun lyfjaverdskra, MoH deltio timwn, NEAK PUPHA, NHRA, PBS. Nexara Health re-checks these sources weekly and shows the last verification date at the top of the page.

Source: Health Canada Drug Product Database (DPD), DIN 02504626, status date 2021-06-22; national medicine registries: BDA, CNOPS liste des medicaments, CNS liste positive, DH Drug Office, eEKO (Erstattungskodex), EMA centrally authorised, EU national register, Fimea Perusrekisteri, HPRA, HZZO, Laegemiddelstyrelsen, Lyfjastofnun lyfjaverdskra, Medicines Authority, MoH deltio timwn, NEAK PUPHA, NHRA, NPRA, PBS, SUKL DLP; price sources: EDE, eEKO (Erstattungskodex), Lyfjastofnun lyfjaverdskra, MoH deltio timwn, NEAK PUPHA, NHRA, PBS.

Health Canada Drug Product Database (DPD), DIN 02504626, status date 2021-06-22; national medicine registries: BDA, CNOPS liste des medicaments, CNS liste positive, DH Drug Office, eEKO (Erstattungskodex), EMA centrally authorised, EU national register, Fimea Perusrekisteri, HPRA, HZZO, Laegemiddelstyrelsen, Lyfjastofnun lyfjaverdskra, Medicines Authority, MoH deltio timwn, NEAK PUPHA, NHRA, NPRA, PBS, SUKL DLP; price sources: EDE, eEKO (Erstattungskodex), Lyfjastofnun lyfjaverdskra, MoH deltio timwn, NEAK PUPHA, NHRA, PBS. Last reviewed 2026-09-16. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.